Among those with a baseline IPSS Q7 score 2 , more patients with combination therapy had a score < 2 at month 48 ( 34 % ) compared with dutasteride ( 30 % , p = 0.018 ) or tamsulosin ( 26 % , p < 0.0001 ) .